• AMA with Certified Student Loan Professional

    Join SDN on December 7th at 6:00 PM Eastern as we host Andrew Paulson of StudentLoanAdvice.com for an AMA webinar. He'll be answering your questions about how to best manage your student loans. Register now!

"New" indication for breast RT?

BobbyHeenan

Full Member
7+ Year Member
Mar 20, 2013
1,210
1,752
  1. Attending Physician
    Can someone please run an over age 70 stage I three arm trial of 5 fraction APBI versus AI versus AI+APBI? Is someone working on this?

    I'm thinking no survival difference. QoL and cost better with APBI alone. NO need for bone strengthening meds and misery of hot flashes and joint aches.
     
    • Like
    Reactions: 3 users

    BobbyHeenan

    Full Member
    7+ Year Member
    Mar 20, 2013
    1,210
    1,752
    1. Attending Physician
      Aside...

      I've adopted this strategy and took it from a wise breast rad onc attending in training.

      If patient initially declines XRT and wants to do an AI I schedule them a follow up with me or nurse navigator at 1 month s/p AI. If they're miserable or having bothersome side effects, I then push harder on XRT...because VERY likely (as noted above) there's not way in hell they're completing 5 years.
       
      • Like
      Reactions: 5 users
      About the Ads

      medgator

      Persona Non Grata
      Lifetime Donor
      15+ Year Member
      Sep 20, 2004
      8,854
      7,336
      1. Attending Physician
        Aside...

        I've adopted this strategy and took it from a wise breast rad onc attending in training.

        If patient initially declines XRT and wants to do an AI I schedule them a follow up with me or nurse navigator at 1 month s/p AI. If they're miserable or having bothersome side effects, I then push harder on XRT...because VERY likely (as noted above) there's not way in hell they're completing 5 years.
        I do the same but usually 2-3 months out, try to give xrt by 12 weeks out from surgery
         

        scarbrtj

        I Don't Like To Bragg
        5+ Year Member
        Dec 18, 2015
        3,216
        4,916
        1. Attending Physician
          Yup.

          But the calculus has changed. In the era of the CALGB trial it was 6 weeks.

          Now it could be just 5 treatments with fancy treatment with nearly zero toxicity.
          It's slow day Friday which means time for a graph.
          The one week regimen has severe implications for linac utilization in the U.S.

          kd2VHZa.png
           
          • Like
          Reactions: 1 users

          evilbooyaa

          Full Member
          Staff member
          Volunteer Staff
          10+ Year Member
          Verified Expert
          Oct 10, 2011
          7,378
          8,072
          1. Attending Physician
            Main issue with breast RT in the old days was 2D planning and lack of field in field, resulting in significant hotspots, which lead to significant burn.

            While there is a slight long-term cosmetic advantage to moderate hypofrac (15-16 fx) that is not maintained on the 'good' 5-fraction data (underpowered, but numerically higher rates of adverse issues 5-fraction both in 28.5/5 in FAST and 26/5 in FAST-FORWARD when compared to 15-16 fx).
             

            medgator

            Persona Non Grata
            Lifetime Donor
            15+ Year Member
            Sep 20, 2004
            8,854
            7,336
            1. Attending Physician
              Main issue with breast RT in the old days was 2D planning and lack of field in field, resulting in significant hotspots, which lead to significant burn.

              While there is a slight long-term cosmetic advantage to moderate hypofrac (15-16 fx) that is not maintained on the 'good' 5-fraction data (underpowered, but numerically higher rates of adverse issues 5-fraction both in 28.5/5 in FAST and 26/5 in FAST-FORWARD when compared to 15-16 fx).
              Maybe 15-16 fx is that sweet spot
               
              • Like
              Reactions: 3 users

              BobbyHeenan

              Full Member
              7+ Year Member
              Mar 20, 2013
              1,210
              1,752
              1. Attending Physician
                Maybe 15-16 fx is that sweet spot

                For whole breast, I think you may be right.

                For partial breast I’m becoming a 30/5 believer ( * knowing the smaller #s and CIs from the trial may not inspire confidence...but for the 50%+ of patients that will never complete an AI it’s at least better than 0 Gy...high bar, I know).
                 
                • Like
                Reactions: 1 users

                Palex80

                RAD ON
                10+ Year Member
                Dec 17, 2007
                2,347
                1,974
                41
                Europe
                1. Attending Physician
                  Indeed, what we are about to witness in breast is huge. Look at what the CHHiP trial in the UK has lead to

                  Around 16k patients in the UK receive primary RT for prostate cancer per year.
                  16k x 37 fractions --> 592.000 fractions (assuming 37 x 2 Gy) per year
                  16k x 20 fractions --> 320.000 fractions (assumung 20 x 3 Gy - the "winner" regime in CHHiP) per year

                  That's 272.000 fractions less per year.
                  Assuming 255 days per year when RT is delivered (365 - weekends - 5 days for holidays) --> 1066 fractions per day less.

                  Let's assume 30 patients per LINAC per day, that would mean 35 less LINACs needed (including staff) for the UK.
                   
                  • Like
                  Reactions: 2 users

                  FrostyHammer

                  Full Member
                  5+ Year Member
                  Aug 20, 2014
                  564
                  957
                  1. Resident [Any Field]
                    Can someone please run an over age 70 stage I three arm trial of 5 fraction APBI versus AI versus AI+APBI? Is someone working on this?

                    I'm thinking no survival difference. QoL and cost better with APBI alone. NO need for bone strengthening meds and misery of hot flashes and joint aches.
                    I was told that NRG is developing this concept - for all the flak academic rad oncs get on this forum, appreciate them for this concept.
                     
                    • Like
                    Reactions: 1 users

                    scarbrtj

                    I Don't Like To Bragg
                    5+ Year Member
                    Dec 18, 2015
                    3,216
                    4,916
                    1. Attending Physician
                      Indeed, what we are about to witness in breast is huge. Look at what the CHHiP trial in the UK has lead to

                      Around 16k patients in the UK receive primary RT for prostate cancer per year.
                      16k x 37 fractions --> 592.000 fractions (assuming 37 x 2 Gy) per year
                      16k x 20 fractions --> 320.000 fractions (assumung 20 x 3 Gy - the "winner" regime in CHHiP) per year

                      That's 272.000 fractions less per year.
                      Assuming 255 days per year when RT is delivered (365 - weekends - 5 days for holidays) --> 1066 fractions per day less.

                      Let's assume 30 patients per LINAC per day, that would mean 35 less LINACs needed (including staff) for the UK.
                      If it were suddenly known that a lucrative drug’s utilization were going to fall by 50 plus percent, that company’s market capitilzation would take a big hit. Aside from the drop in radiation oncology popularity for med students (which hasn’t been as negatively proportional to the drop in XRT utilizations we’re talking about TBH), haven’t seen a similar drop in the “rad onc market cap.” We know in rad onc that you can’t cheat physics. Will rad onc be able to cheat economics?
                       
                      • Like
                      Reactions: 1 user

                      medgator

                      Persona Non Grata
                      Lifetime Donor
                      15+ Year Member
                      Sep 20, 2004
                      8,854
                      7,336
                      1. Attending Physician
                        If it were suddenly known that a lucrative drug’s utilization were going to fall by 50 plus percent, that company’s market capitilzation would take a big hit. Aside from the drop in radiation oncology popularity for med students (which hasn’t been as negatively proportional to the drop in XRT utilizations we’re talking about TBH), haven’t seen a similar drop in the “rad onc market cap.” We know in rad onc that you can’t cheat physics. Will rad onc be able to cheat economics?
                        The closest thing one can come to "shorting" rad onc would be to short Varian Elekta and accuray stock?
                         

                        scarbrtj

                        I Don't Like To Bragg
                        5+ Year Member
                        Dec 18, 2015
                        3,216
                        4,916
                        1. Attending Physician
                          The closest thing one can come to "shorting" rad onc would be to short Varian Elekta and accuray stock?
                          Varian stock price would be one indicator among many. (Note to VAR: fund a COVID study.) However the linacs are very underutilized worldwide. A big decrease in US utilization may be offset by increased linac purchases in other developing countries. (So when I say rad onc market cap I’m being a little creative/cutesy; thinking about residency programs and their sizes, rad onc salaries, rad onc unemployment rates etc.)
                           
                          • Like
                          Reactions: 1 user

                          medgator

                          Persona Non Grata
                          Lifetime Donor
                          15+ Year Member
                          Sep 20, 2004
                          8,854
                          7,336
                          1. Attending Physician
                            Varian stock price would be one indicator among many. (Note to VAR: fund a COVID study.) However the linacs are very underutilized worldwide. A big decrease in US utilization may be offset by increased linac purchases in other developing countries. (So when I say rad onc market cap I’m being a little creative/cutesy; thinking about residency programs and their sizes, rad onc salaries, rad onc unemployment rates etc.)
                            Elekta and accuray stock look God awful the last several years, reinforcing that Varian is a de facto monopoly in the business
                             
                            • Like
                            Reactions: 1 user

                            Palex80

                            RAD ON
                            10+ Year Member
                            Dec 17, 2007
                            2,347
                            1,974
                            41
                            Europe
                            1. Attending Physician
                              If it were suddenly known that a lucrative drug’s utilization were going to fall by 50 plus percent, that company’s market capitilzation would take a big hit. Aside from the drop in radiation oncology popularity for med students (which hasn’t been as negatively proportional to the drop in XRT utilizations we’re talking about TBH), haven’t seen a similar drop in the “rad onc market cap.” We know in rad onc that you can’t cheat physics. Will rad onc be able to cheat economics?
                              Well there is one such drug right now...
                              Denosumab (Xgeva) is still being given every 4 weeks for patients with bone metastases. Numerous trials are running and some have already reported preliminary results where the effect of Denosumab is the same if given every 3 months (or even less frequent) at the same dose it is being given now every 4 weeks (and partially with less side-effects too). Once this becomes s.o.c. Xgeva-sales are going to drop > 50%.
                               
                              • Like
                              Reactions: 1 users

                              medgator

                              Persona Non Grata
                              Lifetime Donor
                              15+ Year Member
                              Sep 20, 2004
                              8,854
                              7,336
                              1. Attending Physician
                                • Like
                                Reactions: 1 user
                                About the Ads
                                This thread is more than 1 year old.

                                Your message may be considered spam for the following reasons:

                                1. Your new thread title is very short, and likely is unhelpful.
                                2. Your reply is very short and likely does not add anything to the thread.
                                3. Your reply is very long and likely does not add anything to the thread.
                                4. It is very likely that it does not need any further discussion and thus bumping it serves no purpose.
                                5. Your message is mostly quotes or spoilers.
                                6. Your reply has occurred very quickly after a previous reply and likely does not add anything to the thread.
                                7. This thread is locked.